Unfortunately, due to the high risk of severe side effects linked to Kv11.1 function loss, including ventricular fibrillation, the use of Kv11.1 blocker molecules is discouraged for cancer therapy. The gene discussed is KCNH2; the disease is ventricular fibrillation.